Amyris, Inc. (NASDAQ:AMRS – Get Rating) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 51,680,000 shares, a growth of 6.9% from the February 13th total of 48,350,000 shares. Approximately 21.0% of the company’s shares are short sold. Based on an average daily trading volume, of 5,870,000 shares, the days-to-cover ratio is presently 8.8 days.
Analysts Set New Price Targets
Separately, Piper Sandler cut their target price on Amyris from $2.50 to $2.00 in a research note on Tuesday, January 3rd. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to MarketBeat, Amyris presently has a consensus rating of “Hold” and a consensus target price of $4.67.
Institutional Trading of Amyris
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its position in Amyris by 2.7% in the 1st quarter. BlackRock Inc. now owns 21,667,736 shares of the biotechnology company’s stock worth $94,470,000 after buying an additional 575,957 shares during the last quarter. Vanguard Group Inc. boosted its stake in Amyris by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 19,793,472 shares of the biotechnology company’s stock worth $57,797,000 after purchasing an additional 712,965 shares during the period. State of Michigan Retirement System boosted its stake in Amyris by 6.3% in the 4th quarter. State of Michigan Retirement System now owns 7,645,000 shares of the biotechnology company’s stock worth $11,697,000 after purchasing an additional 450,000 shares during the period. Edmond DE Rothschild Holding S.A. raised its holdings in shares of Amyris by 4.7% during the 3rd quarter. Edmond DE Rothschild Holding S.A. now owns 7,293,700 shares of the biotechnology company’s stock worth $21,298,000 after acquiring an additional 328,000 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Amyris by 6.9% during the 3rd quarter. State Street Corp now owns 4,383,740 shares of the biotechnology company’s stock worth $12,801,000 after acquiring an additional 283,546 shares in the last quarter. Institutional investors own 43.08% of the company’s stock.
Amyris Stock Performance
Amyris Company Profile
Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.